Descriptive table of circulatory variables during CPB. by Vincent Pey (21433304)

Subjects:

Glucose/galactose with extended interferon-priming does not impact levels of ISG RNAs or non-ISG proteins levels. by Tyron Chang (9922533)

Potato gene ontology enrichment results significant at <i>p</i> < 0.01. by Margaret A. Carpenter (6104180)

Genome-wide significant SNPs for meat L*15 min and a*15 min. by Jiahong Sun (6497603)

Statistically Significant Results for Heart Rate Variability (HRV) Indices for High and Low Authority Groups. by David Vagni (8060432)

Subjects:

Statistically Significant Results for Heart Rate Variability (HRV) Indices for High and Low Clarity Groups. by David Vagni (8060432)

Subjects:

Identification of ACADM, ANGPTL4, and NFKB2 as significant predictors of OS in the TCGA-KIRC cohort. by Yu Zhang (12946)

Subjects:

Distinct and shared gene expression patterns among leukemia cell lines following EF-24 treatment. by Ajeet P. Singh (22298432)

Subjects:

EF-24 treatment induces distinct gene expression changes in Kasumi-1 cells. by Ajeet P. Singh (22298432)

Subjects:

EF-24 treatment alters gene expression profiles in HL-60 cells. by Ajeet P. Singh (22298432)

Subjects:

Expression analysis of downstream target genes in the IL-10 signaling pathway across myeloid leukemia cell lines. by Ajeet P. Singh (22298432)

Subjects:

EF-24 treatment modulates gene expression in THP-1 cells. by Ajeet P. Singh (22298432)

Subjects:

Expression analysis of downstream target genes in the p38/MAPK signaling pathway across myeloid leukemia cell lines. by Ajeet P. Singh (22298432)

Subjects:

EF-24 treatment disrupts key molecular pathways associated with cell survival, proliferation, and viability. by Ajeet P. Singh (22298432)

Subjects:

Segmented regression analysis of time to intravenous antimicrobial administration (IVA) at intervention and control sites during the implementation period. by J Mark Ansermino (13958512)

Subjects:

Interrupted time series analysis showing time to intravenous antimicrobials (IVA) in minutes at intervention and control sites in Uganda during baseline and implementation periods. by J Mark Ansermino (13958512)

Subjects:

Kenya: Enrolment, time to IVA, mortality, admissions and readmissions at sites in Kenya. by J Mark Ansermino (13958512)

Subjects:

Uganda: enrolment, time to IVA, mortality, admissions and readmissions. by J Mark Ansermino (13958512)

Subjects:

Interrupted time series analysis showing time to intravenous antimicrobials (IVA) in minutes at intervention and control sites in Kenya during baseline and implementation periods. by J Mark Ansermino (13958512)

Subjects:

Flow diagram of the Smart Triage multisite interventional study in Uganda and Kenya indicating the progress through study phases at each site. by J Mark Ansermino (13958512)

Subjects: